神经源性异位骨化。文献综述。第二部分

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

论证。神经源性异位骨化是由于各种病因造成的严重脑损伤或脊髓损伤导致的身体软组织骨形成。在神经源性异位骨化中，髋关节最常受到影响。

本研究旨在分析有关髋关节神经源性异位骨化的器械诊断、手术和非手术治疗方法及预防的出版物。

材料和方法。综述的第二部分重点介绍神经源性异位骨化髋关节的现代诊断、手术和保守治疗、预防和复发。数据搜索是在科学文献数据库PubMed、Google Scholar、Cochrane Library、Crossref、eLibrary中进行，无语言限制。

结果。目前的诊断方法可以对髋关节神经源性异位骨化的高危患者进行筛查，随后通过计算机断层扫描或磁共振成像进行确诊。尽管目前对切除髋关节神经源性异位骨化的时机尚未达成共识，但手术治疗是切除或减少其体积的最有效方法。在大多数情况下，疼痛综合征得到控制，患者的生活质量得到改善。由于病因因素（中枢神经系统损伤）的共性，对于脊髓损伤、颅脑外伤和小儿脑瘫导致的髋关节神经源性异位骨化患者，非手术方法的预防和治疗效果也不同。

结论。考虑到中枢神经系统病变的原因，随机对照试验将确定保守治疗方法在预防神经源性异位髋关节骨化形成和复发方面的有效性。

作者简介

Vladimir A. Novikov

H. Turner National Medical Research Center for Сhildren’s Orthopedics and Trauma Surgery

Email: novikov.turner@gmail.com
ORCID iD: 0000-0002-3754-4090
SPIN 代码: 2773-1027

MD, PhD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Alina M. Khodorovskaya

H. Turner National Medical Research Center for Сhildren’s Orthopedics and Trauma Surgery

编辑信件的主要联系方式.
Email: alinamyh@gmail.com
ORCID iD: 0000-0002-2772-6747
SPIN 代码: 3348-8038

MD, Research Associate

俄罗斯联邦, Saint Petersburg

Valery V. Umnov

H. Turner National Medical Research Center for Сhildren’s Orthopedics and Trauma Surgery

Email: umnovvv@gmail.com
ORCID iD: 0000-0002-5721-8575
SPIN 代码: 6824-5853

MD, PhD, Dr. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Evgenii V. Melchenko

H. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery

Email: emelchenko@gmail.com
ORCID iD: 0000-0003-1139-5573
SPIN 代码: 1552-8550

MD, PhD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Dmitry V. Umnov

H. Turner National Medical Research Center for Сhildren’s Orthopedics and Trauma Surgery

Email: dmitry.umnov@gmail.com
ORCID iD: 0000-0003-4293-1607
SPIN 代码: 1376-7998

MD, PhD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

参考

  1. Deev RV, Bersenev AV. Rol’ stvolovykh stromal’nykh (mezenkhimal’nykh) kletok v formirovanii geterotopicheskikh ossifikatov. Kletochnaya transplantologiya i tkanevaya inzheneriya. 2005;(1):46–48. (In Russ.)
  2. Meyers C, Lisiecki J, Miller S, et al. Heterotopic ossification: a comprehensive review. JBMR Plus. 2019;3(4). doi: 10.1002/jbm4.10172
  3. Brady RD, Shultz SR, McDonald SJ, et al. Neurological heterotopic ossification: Current understanding and future directions. Bone. 2018;109:35–42. doi: 10.1016/j.bone.2017.05.015
  4. Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Orthop Relat Res. 1989;(242):169–176. doi: 10.1097/00003086-198905000-00016
  5. Ippolito E, Formisano R, Caterini R, et al. Operative treatment of heterotopic hip ossification in patients with coma after brain injury. Clin Orthop Relat Res. 1999;(365):130–138. doi: 10.1097/00003086-199908000-00018
  6. Wong KR, Mychasiuk R, O’Brien TJ, et al. Neurological heterotopic ossification: novel mechanisms, prognostic biomarkers and prophylactic therapies. Bone Res. 2020;8(1):42. doi: 10.1038/s41413-020-00119-9
  7. Arduini M, Mancini F, Farsetti P, Piperno A, Ippolito E. A new classification of peri-articular heterotopic ossification of the hip associated with neurological injury: 3D CT scan assessment and intra-operative findings. Bone Joint J. 2015;97-B(7):899–904. doi: 10.1302/0301-620X.97B7.35031
  8. de l’Escalopier N, Denormandie P, Gatin L, et al. Resection of neurogenic heterotopic ossification (NHO) of the hip, lessons learned after 377 procedures. Annals of Physical and Rehabilitation Medicine. 2018;61. doi: 10.1016/j.rehab.2018.05.385
  9. Zielinski E, Chiang BJL, Satpathy J. The role of preoperative vascular imaging and embolisation for the surgical resection of bilateral hip heterotopic ossification. BMJ Case Rep. 2019;12(8). doi: 10.1136/bcr-2019-230964.
  10. Cholok D, Chung MT, Ranganathan K, et al. Heterotopic ossification and the elucidation of pathologic differentiation. Bone. 2018;109:12–21. doi: 10.1016/j.bone.2017.09.019
  11. Svircev JN, Wallbom AS. False-negative triple-phase bone scans in spinal cord injury to detect clinically suspect heterotopic ossification: a case series. J Spinal Cord Med. 2008;31(2):194–196. doi: 10.1080/10790268.2008.11760711
  12. van Kuijk AA, Geurts AC, van Kuppevelt HJ. Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord. 2002;40(7):313–326. doi: 10.1038/sj.sc.3101309
  13. Denormandie P, de l’Escalopier N, Gatin L, et al. Resection of neurogenic heterotopic ossification (NHO) of the hip. Orthop Traumatol Surg Res. 2018;104(1S):S121–S127. doi: 10.1016/j.otsr.2017.04.015
  14. Mujtaba B, Taher A, Fiala MJ, et al. Heterotopic ossification: radiological and pathological review. Radiol Oncol. 2019;53(3):275–284. doi: 10.2478/raon-2019-0039
  15. Wang H, Nie P, Li Y, et al. MRI findings of early myositis ossificans without calcification or ossification. Biomed Res Int. 2018;2018. doi: 10.1155/2018/4186324
  16. Stefanidis K, Brindley P, Ramnarine R, et al. Bedside ultrasound to facilitate early diagnosis and ease of follow-up in neurogenic heterotopic ossification: a pilot study from the intensive care unit. J Head Trauma Rehabil. 2017;32(6):E54–E58. doi: 10.1097/HTR.0000000000000293
  17. Wang Q, Zhang P, Li P, et al. Ultrasonography monitoring of trauma-induced heterotopic ossification: guidance for rehabilitation procedures. Front Neurol. 2018;9:771. doi: 10.3389/fneur.2018.00771
  18. Rosteius T, Suero EM, Grasmücke D, et al. The sensitivity of ultrasound screening examination in detecting heterotopic ossification following spinal cord injury. Spinal Cord. 2017;55(1):71–73. doi: 10.1038/sc.2016.93.
  19. Garland DE. A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop Relat Res. 1991;(263):13–29. doi: 10.1097/00003086-199102000-00003
  20. Mavrogenis AF, Guerra G, Staals EL, et al. A classification method for neurogenic heterotopic ossification of the hip. J Orthop Traumatol. 2012;13(2):69–78. doi: 10.1007/s10195-012-0193-z
  21. Della Valle AG, Ruzo PS, Pavone V, et al. Heterotopic ossification after total hip arthroplasty: a critical analysis of the Brooker classification and proposal of a simplified rating system. J Arthroplasty. 2002;17(7):870–875. doi: 10.1054/arth.2002.34819
  22. Brooker AF, Bowerman JW, Robinson RA, et al. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am. 1973;55(8):1629–1632.
  23. Genet F, Marmorat JL, Lautridou C, et al. Impact of late surgical intervention on heterotopic ossification of the hip after traumatic neurological injury. J Bone Joint Surg Br. 2009;91(11):1493–1498. doi: 10.1302/0301-620X.91B11.22305
  24. Genêt F, Jourdan C, Schnitzler A, et al. Troublesome heterotopic ossification after central nervous system damage: a survey of 570 surgeries. PLoS One. 2011;6(1). doi: 10.1371/journal.pone.0016632
  25. Taunton MJ. Heterotopic Ossification. In: Complications after primary total hip arthroplasty: a comprehensive clinical guide. Ed. by M.P. Abdel, C.J. Della Valle. Springer Cham; 2017. P. 213–224.
  26. Cobb TK, Berry DJ, Wallrichs SL, et al. Functional outcome of excision of heterotopic ossification after total hip arthroplasty. Clin Orthop Relat Res. 1999;(361):131–139. doi: 10.1097/00003086-199904000-00018
  27. Moore TJ. Functional outcome following surgical excision of heterotopic ossification in patients with traumatic brain injury. J Orthop Trauma. 1993;7(1):11–14. doi: 10.1097/00005131-199302000-00003
  28. Almangour W, Schnitzler A, Salga M, et al. Recurrence of heterotopic ossification after removal in patients with traumatic brain injury: a systematic review. Ann Phys Rehabil Med. 2016;59(4):263–269. doi: 10.1016/j.rehab.2016.03.009
  29. Chalidis B, Stengel D, Giannoudis PV. Early excision and late excision of heterotopic ossification after traumatic brain injury are equivalent: a systematic review of the literature. J Neurotrauma. 2007;24(11):1675–1686. doi: 10.1089/neu.2007.0342
  30. Macheras GA, Lepetsos P, Leonidou A, et al. Results from the surgical resection of severe heterotopic ossification of the hip: a case series of 26 patients. Eur J Orthop Surg Traumatol. 2017;27(8):1097–1102. doi: 10.1007/s00590-017-1980-2
  31. Behery OA, Dai AZ, McLaurin TM. Posttraumatic heterotopic ossification of the hip. J Orthop Trauma. 2018;32(1):S18–S19. doi: 10.1097/BOT.0000000000001197
  32. Meiners T, Abel R, Böhm V, et al. Resection of heterotopic ossification of the hip in spinal cord injured patients. Spinal Cord. 1997;35(7):443–445. doi: 10.1038/sj.sc.3100415
  33. Dilling CF, Wada AM, Lazard ZW, et al. Vessel formation is induced prior to the appearance of cartilage in BMP-2-mediated heterotopic ossification. J Bone Miner Res. 2010;25(5):1147–1156. doi: 10.1359/jbmr.091031
  34. Kim JH, Park C, Son SM, et al. Preoperative arterial embolization of heterotopic ossification around the hip joint. Yeungnam Univ J Med. 2018;35(1):130–134. doi: 10.12701/yujm.2018.35.1.130
  35. Papalexis N, Peta G, Errani C, et al. Preoperative arterial embolization for heterotopic ossification of the hip. J Vasc Interv Radiol. 2023;34(4):608–612. doi: 10.1016/j.jvir.2022.11.030
  36. Koulouvaris P, Tsailas P, Tsiavos K, et al. Clinical observations on surgical details of resection of heterotopic ossification at the hip in traumatic brain-injured adult. J Surg Orthop Adv. 2010;19(3):177–180.
  37. Gatin L, Genêt F, Dinh A, et al. Postoperative infections after excision of neurogenic heterotopic ossifications at the hip: Risk factors and causative organisms. Orthop Traumatol Surg Res. 2017;103(3):357–361. doi: 10.1016/j.otsr.2017.02.001
  38. Stover SL, Niemann KM, Tulloss JR. Experience with surgical resection of heterotopic bone in spinal cord injury patients. Clin Orthop Relat Res. 1991;(263):71–77.
  39. Xu Y, Huang M, He W, et al. Heterotopic ossification: clinical features, basic researches, and mechanical stimulations. Front Cell Dev Biol. 2022;10. doi: 10.3389/fcell.2022.770931
  40. Huber AK, Patel N, Pagani CA, et al. Immobilization after injury alters extracellular matrix and stem cell fate. J Clin Invest. 2020;130(10):5444–5460. doi: 10.1172/JCI136142
  41. Jones NA, Bentley BC, Wahl L. Nonsurgical management of heterotopic ossification in a runner. J Orthop Sports Phys Ther. 2019;49(9):676. doi: 10.2519/jospt.2019.8491
  42. Crawford CM, Varghese G, Mani MM, et al. Heterotopic ossification: are range of motion exercises contraindicated? J Burn Care Rehabil. 1986;7(4):323–327. doi: 10.1097/00004630-198607000-00005
  43. Daud O, Sett P, Burr RG, et al. The relationship of heterotopic ossification to passive movements in paraplegic patients. Disabil Rehabil. 1993;15(3):114–118. doi: 10.3109/09638289309166001
  44. Craven PL, Urist MR. Osteogenesis by radioisotope labelled cell populations in implants of bone matrix under the influence of ionizing radiation. Clin Orthop Relat Res. 1971;76:231–243. doi: 10.1097/00003086-197105000-00030
  45. Wang Y, Zhu G, Wang J, et al. Irradiation alters the differentiation potential of bone marrow mesenchymal stem cells. Mol Med Rep. 2016;13(1):213–223. doi: 10.3892/mmr.2015.4539
  46. Pohl F, Hassel S, Nohe A, et al. Radiation-induced suppression of the Bmp2 signal transduction pathway in the pluripotent mesenchymal cell line C2C12: an in vitro model for prevention of heterotopic ossification by radiotherapy. Radiat Res. 2003;159(3):345–350. doi: 10.1667/0033-7587(2003)159[0345:risotb]2.0.co;2
  47. Georhakopoulos I, Kouloulias V, Kougiountzopoulou A, et al. Radiation therapy for the prevention of heterotopic ossification: efficacy and toxicity of single fraction radiotherapy. Orthop Rev (Pavia). 2020;12(2). doi: 10.4081/or.2020.8577
  48. Davis E, Williams K, Matheney TH, et al. Radiation prophylaxis for hip salvage surgery in cerebral palsy: can we reduce the incidence of heterotopic ossification? J Pediatr Orthop. 2019;39(5):e386–e391. doi: 10.1097/BPO.0000000000001314
  49. Müseler AC, Grasmücke D, Jansen O, et al. In-hospital outcomes following single-dose radiation therapy in the treatment of heterotopic ossification of the hip following spinal cord injury-an analysis of 444 cases. Spinal Cord. 2017;55(3):244–246. doi: 10.1038/sc.2016.112
  50. Schincariol CYN, Echauri EMI, Silvestre OF, et al. Heterotopic ossification after spinal cord injury: prevention and treatment – a sistematic review. Acta Ortop Bras. 2023;31(3). doi: 10.1590/1413-785220233103e267451
  51. Lee CH, Shim SJ, Kim HJ, et al. Effects of radiation therapy on established neurogenic heterotopic ossification. Ann Rehabil Med. 2016;40(6):1135–1139. doi: 10.5535/arm.2016.40.6.1135
  52. Hu ZH, Chen W, Sun JN, et al. Radiotherapy for the prophylaxis of heterotopic ossification after total hip arthroplasty: a systematic review and meta-analysis of randomized controlled trails. Med Dosim. 2021;46(1):65–73. doi: 10.1016/j.meddos.2020.07.010
  53. Milakovic M, Popovic M, Raman S, et al. Radiotherapy for the prophylaxis of heterotopic ossification: A systematic review and meta-analysis of randomized controlled trials. Radiother Oncol. 2015;116(1):4–9. doi: 10.1016/j.radonc.2015.05.022
  54. Ebinger T, Roesch M, Kiefer H, et al. Influence of etiology in heterotopic bone formation of the hip. J Trauma. 2000;48(6):1058–1062. doi: 10.1097/00005373-200006000-00010.
  55. Padgett DE, Holley KG, Cummings M, et al. The efficacy of 500 CentiGray radiation in the prevention of heterotopic ossification after total hip arthroplasty: a prospective, randomized, pilot study. J Arthroplasty. 2003;18(6):677–686. doi: 10.1016/s0883-5403(03)00265-1
  56. Honore T, Bonan I, Salga M, et al. Effectiveness of radiotherapy to prevent recurrence of heterotopic ossification in patients with spinal cord injury and traumatic head injury: a retrospective case-controlled study. J Rehabil Med. 2020;52(5). doi: 10.2340/16501977-2692
  57. Cipriano C, Pill SG, Rosenstock J, et al. Radiation therapy for preventing recurrence of neurogenic heterotopic ossification. Orthopedics. 2009;32(9). doi: 10.3928/01477447-20090728-33
  58. Mourad WF, Packianathan S, Shourbaji RA, et al. Radiation-induced sarcoma following radiation prophylaxis of heterotopic ossification. Pract Radiat Oncol. 2012;2(2):151–154. doi: 10.1016/j.prro.2011.06.005
  59. Farris MK, Chowdhry VK, Lemke S, et al. Osteosarcoma following single fraction radiation prophylaxis for heterotopic ossification. Radiat Oncol. 2012;7:140. doi: 10.1186/1748-717X-7-140
  60. Liu H, Zhao JG, Li Y, et al. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev. 2019;2019(7). doi: 10.1002/14651858.CD012861.pub2
  61. Banovac K, Williams JM, Patrick LD, et al. Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord. 2001;39(7):370–374. doi: 10.1038/sj.sc.3101166
  62. Banovac K, Williams JM, Patrick LD, et al. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord. 2004;42(12):707–710. doi: 10.1038/sj.sc.3101628
  63. Zakrasek EC, Yurkiewicz SM, Dirlikov B, et al. Use of nonsteroidal anti-inflammatory drugs to prevent heterotopic ossification after spinal cord injury: a retrospective chart review. Spinal Cord. 2019;57(3):214–220. doi: 10.1038/s41393-018-0199-3
  64. Yolcu YU, Wahood W, Goyal A, et al. Pharmacologic prophylaxis for heterotopic ossification following spinal cord injury: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2020;193. doi: 10.1016/j.clineuro.2020.105737
  65. Dartnell J, Paterson JM, Magill N, Norman-Taylor F. Proximal femoral resection for the painful dislocated hip in cerebral palsy: does indomethacin prevent heterotopic ossification? J Pediatr Orthop. 2014;34(3):295–299. doi: 10.1097/BPO.0000000000000146
  66. Borgeat A, Ofner C, Saporito A, et al. The effect of nonsteroidal anti-inflammatory drugs on bone healing in humans: a qualitative, systematic review. J Clin Anesth. 2018;49:92–100. doi: 10.1016/j.jclinane.2018.06.020
  67. Stover SL, Hahn HR, Miller JM 3rd. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report). Paraplegia. 1976;14(2):146–156. doi: 10.1038/sc.1976.25
  68. Teasell RW, Mehta S, Aubut JL, et al.; SCIRE Research Team. A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury. Spinal Cord. 2010;48(7):512–521. doi: 10.1038/sc.2009.175
  69. Spielman G, Gennarelli TA, Rogers CR. Disodium etidronate: its role in preventing heterotopic ossification in severe head injury. Arch Phys Med Rehabil. 1983;64(11):539–542.
  70. Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2000;23(1):40–44. doi: 10.1080/10790268.2000.11753507
  71. Shafer DM, Bay C, Caruso DM, et al. The use of eidronate disodium in the prevention of heterotopic ossification in burn patients. Burns. 2008;34(3):355–360. doi: 10.1016/j.burns.2007.04.006
  72. Thomas BJ, Amstutz HC. Results of the administration of diphosphonate for the prevention of heterotopic ossification after total hip arthroplasty. J Bone Joint Surg Am. 1985;67(3):400–403. doi: 10.2106/00004623-198567030-00008
  73. Ploumis A, Donovan JM, Olurinde MO, et al. Association between alendronate, serum alkaline phosphatase level, and heterotopic ossification in individuals with spinal cord injury. J Spinal Cord Med. 2015;38(2):193–198. doi: 10.1179/2045772314Y.0000000213
  74. Schuetz P, Mueller B, Christ-Crain M, et al. Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases. Spinal Cord. 2005;43(10):604–610. doi: 10.1038/sj.sc.3101761

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Эко-Вектор, 2023

Creative Commons License
此作品已接受知识共享署名-禁止演绎 4.0国际许可协议的许可。
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».